Completed PHASE1 INTERVENTIONAL 4-arm NCT05930119

HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study

A Phase 1, Open-label, 4-period, Randomized 6-sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-453 in Healthy Volunteers

Sponsor: Hutchmed

Conditions Intrahepatic Cholangiocarcinoma

Interventions HMPL-453 Rabeprazole

Updated 4 times since 2023 Last updated: Aug 31, 2023 Started: Mar 17, 2023 Primary completion: Aug 28, 2023 Completion: Aug 28, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Intrahepatic Cholangiocarcinoma, this trial is completed. The trial is conducted by Hutchmed and has accumulated 4 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Oct 2023 — Jul 2024 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Aug 2023 — Oct 2023 [monthly]

Active Not Recruiting PHASE1

First recorded

Mar 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hutchmed

Data source: Hutchmed

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China